Excellent, page-3

Gotta have a bit of a chuckle. Isn't the market interested in companies that are:
1. in profit;
2. have strong future cashflow projections;
3. in a segment with stellar growth projections
4. locked into the world's leading market for its area with a great JV partner;
5. well into clinical stages across its product spectrum, where other peers are not...etc..etc.?

One thin I like is that the JV is already in advanced discussions for partnering in areas outside osteoarthritis. Another partnering cashflow stream could potentially be announced any time.